Editorials

Anti-Tumor Necrosis Factor Agents Are Mostly Used in Patients with Established Rheumatoid Arthritis Compared to Early Disease — A Reflection of Adequate Clinical Practice
B. Haraoui .................................................. 1561

Quantitative Clinical Rheumatology: Why Is a Test for Anti-CCP Antibodies Included in Most Routine Care for Rheumatoid Arthritis While a HAQ/MDHAQ Remains Largely a Research Tool?
T. Pincus, Y. Yazici, M.J. Bergman ...................... 1563

Anti-Cyclic Citrullinated Peptide Antibody versus HAQ/MDHAQ: Comparing Apples and Oranges?
V. Bykerk .................................................. 1565

The Many Myths of Erythrocyte Sedimentation Rate and C-Reactive Protein
F. Wolfe .................................................. 1568

Bisphosphonates in Patients with Glucocorticoids: Time for Implementation
W.F. Lems .................................................. 1570

Towards a New Clinico-Immunopathological Classification of Juvenile Inflammatory Arthritis
D. McGonagle, M. Benjamin ................................ 1573

Articles

The TNF-α-blocking Agent Infliximab Inhibits IL-1β and IL-6 Gene Expression in Human Osteoblastic Cells
E. Musacchio, C. Valvason, C. Botsios, et al .................. 1575

Expression and Function of Histone Deacetylases in RA Synovial Fibroblasts
M. Horiuchi, A. Morinobu, T. Chin, Y. Sakai, M. Kurosaka, S. Kumagai ........................................... 1580

Lack of Association with RA of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA

Declines in ESR in Patients with RA Over the Second Half of the 20th Century
B. Abelson, T. Sokka, T. Pincus ........................................ 1596

A Followup Study of Asymptomatic Carriers of P. jiroveci During Immunosuppressive Therapy for RA
S. Mori, I. Cho, M. Sugimoto ........................................ 1600

Which Measure of Inflammation to Use? A Comparison of ESR and CRP Measurements from Randomized Clinical Trials of Golimumab in RA
C.S. Crowson, M.U. Rahman, E.L. Matteson ..................... 1606

Utilization Trends of TNF Inhibitors Among Patients with RA in a US Observational Cohort Study

Severe Disease Activity and Complications of Immunosuppressive Therapy: A Challenge for Acute Hospital-based Rehabilitation in Rheumatology

Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyarthritis Syndrome
C.P. Mavragani, F.N. Skopouli, H.M. Moutsopoulos ................ 1626

Evidence for Genetic Association and Interaction Between the TYK2 and IRF5 Genes in SLE

Changes in Lipid Profile Between Flare and Remission of Patients with SLE: A Prospective Study
M. Uruquizu-Padilla, E. Balada, P. Chacon, E. Hermosilla Pérez, M. Vilardell-Tarrés, J. Ordí-Ros .................. 1639

High Prevalence of Asymptomatic Vertebral Fractures in Chinese Women with SLE
E.K. Li, L.S. Tam, J.F. Griffith, et al .......................... 1646

Improvement of Severe SSc-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with IV Cyclophosphamide
S.W. Schulz, M. O’Brien, M. Maqsood, N. Sanderfer, F. Del Galdo, S.A. Jimenez .................. 1653

Elevated Circulating TWEAK Levels in SSc: Association with Lower Frequency of Pulmonary Fibrosis

Diagnosis of Raynaud’s Phenomenon by 99mTc-HDP Digital Blood Flow Scintigraphy After One-hand Chilling
S-R. Kwon, M-J. Lim, S-G. Park, I-Y. Hyun, W. Park .................. 1663

Clinical and Genetic Features of Familial Mediterranean Fever in Japan
A. Tsuchiya-Suzuki, M. Yazaki, A. Nakamura, et al ................ 1671

Contents continued opposite inside back cover . . .
A Clinical Criterion to Exclude the Hyperimmunoglobulin D Syndrome (Mild Mevalonate Kinase Deficiency) in Patients with Recurrent Fever  
O. Steichen, J. van der Hilst,  
A. Simon, L. Cuisset, G. Grateau  1677

Absence of M. tuberculosis in Arterial Lesions from Patients with Takayasu’s Arteritis  
L. Arnaud, E. Cambau, I. Brocheriou, et al  1682

The Presence of Limited Joint Mobility Is Significantly Associated with Multiple Digit Involvement by Stenosing Flexor Tenosynovitis in Diabetics  
M. Kameyama, S. Meguro, O. Funae, Y. Atsumi, H. Ikegami  1686

Serum Uric Acid Is Independently Associated with Metabolic Syndrome in Subjects with and without a Low Estimated GFR  
L-C. See, C-F. Kuo, F-H. Chuang, et al  1691

Impact of a Rheumatology Consultation Service on the Diagnostic Accuracy and Management of Gout in Hospitalized Patients  
C. Barber, K. Thompson, J.G. Hanly  1699

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial  
S.A. Stoch, K.G. Saag, M. Greenwald, et al  1705

Sensitivity and Specificity of Ultrasonography in Early Diagnosis of Metatarsal Bone Stress Fractures: A Pilot Study of 37 Patients  
F. Banal, F. Gandjbakhch, V. Foltz, et al  1715

Increased Frequency of GI Symptoms in Patients with Fibromyalgia and Associated Factors: A Comparative Study  
Ö.N. Pamuk, H. Ümit, O. Harmandar  1720

Pediatric Rheumatology

Ankle Disease in JIA: Ultrasound Findings in Clinically Swollen Ankles  
M.E. Rooney, C. McAllister, J.F.T. Burns  1725

Th1 and Th17 Predominance in the Enthesitis-related Arthritis Form of JIA  
A. Mahendra, R. Misra, A. Agganwal  1730

Biomarkers of Chronic Uveitis in JIA: Predictive Value of Antihistone Antibodies and Antinuclear Antibodies  
E.B. Nordal, N.T. Songstad, L. Berntson, T. Moen, B. Straume, M. McQueen, et al  1737

Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases  
A. Brucato, C. Grava, M. Bortolati, et al  1744

Cartilage Oligomeric Matrix Protein in Patients with JIA: Relation to Growth and Disease Activity  
B. Bjørnhart, A. Juul, S. Nielsen, M. Zak, P. Svenningsen, K. Müller  1749

Surfing for JIA: Perspectives on Quality and Content of Information on the Internet  
J.N. Stinson, L. Tucker, A. Huber, et al  1755

Images in Rheumatology

The Radiographic Scars of Glucocorticoid Treatment in SLE  
J.W. Maynard, A.C. Gelber  1763


Introduction  
P. Tugwell, M. Boers, V. Strand, L.S. Simon, P. Brooks  1767

Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature Search on 5 Candidate Biomarkers  
S.W. Syversen, R. Landewé, D. van der Heijde, et al  1769

Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis:  
The OMERACT 9 v2 Criteria  
W.P. Maksymowych, R. Landewé, P-P. Tak, et al  1785

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design  

Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in RA Clinical Trials: Consistency Across Centers  
B. Bresnihan, E. Pontifex, R.M. Thurlings, et al  1800

The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities  
P.G. Conaghan, P. Bird, F. McQueen, et al  1803

Reducing Invasiveness, Duration, and Cost of MRI in RA by Omitting IV Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?  
M. Østergaard, P.G. Conaghan, P. O’Connor, et al  1806

Testing an OMERACT MRI Scoring System for Peripheral PsA in Cross-sectional and Longitudinal Settings  
F. McQueen, M. Lassere, A. Duer-Jensen, et al  1811

The OMERACT PsA MRI Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands  
M. Østergaard, F. McQueen, C. Wiell, et al  1816

Multiple Computer-based Methods of Measuring JSW Can Discriminate Between Treatment Arms in the COBRA Trial — Update of an Ongoing OMERACT Project  
J.T. Sharp, J. Angwin, M. Boers, et al  1825

The OMERACT Ultrasound Task Force — Advances and Priorities  

Correspondence

 Missing the Obvious  
D.M. Nuenninghoff  1833

Reply  
P. Claudepierre  1833
Limitations of ANA Tests (HEp-2) Are Overcome with the Autoimmune Target Test (IT-1) in SLE
L-H. Jearn, D-A. Kim, T-Y. Kim .......................... 1833

Reply
T. Skogh, A.A. Bengtsson, C. Dahle, et al. ......... 1834

Letters
Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy
A.N. Lau, J.D. Adachi ............................. 1835

Interaction of Human Recombinant TNF-Related Apoptosis-Inducing Ligand and Osteoprotegerin Could Contribute to Enhancement of the Erosive Processes Induced by Human Synovial Cells
P. Narducci, R. Bareggi, V. Nicolin .......... 1837

Thymoglobulin and Cyclophosphamide as Treatment for Diffuse Cutaneous Systemic Sclerosis
L.A. Holmberg, D.E. Furst, P.A. McSweeney, R.A. Nash .... 1839

Steroid Injection Performed with Fluoroscopy for Treatment of a Discal Cyst
T. Dumay-Levesque, A-C. Souteyrand, J-L. Michel .... 1841

Assessing Mitral Valve Stenosis by Real-time 3-Dimensional Echocardiography in SLE: A Look Inside the Heart
S.C. Plastiras, C.A. Pamboucas, G.E. Tzelepis,
S.T. Toumanidis ................................. 1843

Mimics of Vasculitis: Vascular Ehlers-Danlos Syndrome Masquerading as Polyarteritis Nodosa
R.A. Badawi, L.H. Brent, D.E. Feinstein .......... 1845

Atypical Symptom of Ehlers-Danlos Syndrome Impeding Diagnosis: Feeling of Spinal Instability
R. Gasik, T. Styczynski .......................... 1847

Painful Lower Extremities Related to Diaphyseal Dysplasia: Genetic Diagnosis and Treatment
S.L.E. Ribeiro, E.L. Guedes, V.M.G. Prazeres,
E.J.G. de Freitas, A.R.C. Fernandes ........ 1848

Corrections
Assessment and Management of Rheumatoid Arthritis
B. Haraoui ................................. 1851

Serum Urate During Acute Gout
N. Schlesinger, J.M. Norquist, D.J. Watson .... 1851

Meetings in Rheumatology ..........................